TICKERNERD
Menu
BDMDBDMDHealthcare · Medical Devices

BDMD Stock Forecast: Baird Medical Investment Holdings Ltd. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.16
−14.68% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$6.0M
Ticker Nerd rank
49/ 100
Median analyst target
$4.00
Analysts covering
0
Total return, dividends reinvested
1W
−64.0%
1M
−79.4%
YTD
−88.2%
1Y
−88.5%
From 52W high
−95.3%
From 52W low
0.0%
$0.16
$3.44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BDMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Baird Medical Investment Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
49/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
96
Size
94
Value
92
Issuance
54
Quality
40
Revisions
37
Volatility
30
Growth
8
Momentum
6

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BDMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BDMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26BDMDHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BDMD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BDMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Baird Medical Investment Holdings Ltd. returned −88.5% against +12.4% for the S&P 500, dividends included.

BDMD vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Jan 26Apr 26Jul 26Oct 26BDMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BDMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Baird Medical Investment Holdings Ltd. (BDMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.2×

Cheaper than 68% of US stocks

Price / sales
0.3×

Cheaper than 88% of US stocks

Price / book
0.2×

Cheaper than 88% of US stocks

EV / EBITDA
−1.8×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
24.6%

Higher than 74% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
8.5%

Higher than 62% of US stocks

Net margin
−65.1%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−46.0%

Higher than 22% of US stocks

Return on assets
−11.9%

Higher than 25% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Baird Medical Investment Holdings Ltd. (BDMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Baird Medical Investment Holdings Ltd. has a market value of $6.0M and an enterprise value of $24.3M.

  • Shares outstanding: 30.8M.

  • Trailing P/E: 3.2×; forward P/E: 1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Baird Medical Investment Holdings Ltd. employs 146 people.

market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

BDMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BDMDBaird Medical Investment Holdings Ltd.$6.0M49
VNRXVolitionRX Ltd.$5.4M43
TNONTENON Medical, Inc.$5.5M51
NVNOenVVeno Medical Corp.$4.7M28
INBSIntelligent Bio Solutions, Inc.$5.8M16
WOKWORK Medical Technology Group Ltd.$4.5M17
VVOSVivos Therapeutics, Inc.$3.8M37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Baird Medical Investment Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BDMD news & analysis

Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology

GlobeNewsWire · 19 Oct 2026positive

Baird Medical announced regulatory milestones in Vietnam and Egypt for its microwave ablation technology. The company said it continues to advance its global regulatory strategy while supporting U.S. commercial expansion.

Why it matters — The announced milestones reflect progress in BDMD’s international regulatory efforts and its ongoing U.S. commercial expansion.

Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026

GlobeNewsWire · 5 Oct 2026positive

Baird Medical reported key third-quarter 2026 developments, including expansion into new international markets, continued physician training initiatives, and the addition of irreversible electroporation (IRE) technology to its portfolio through a strategic partnership.

Why it matters — The expansion into new markets and addition of IRE technology signal growth in Baird Medical's global reach and technological capabilities.

Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 15 Sept 2026neutral

Baird Medical Investment Holdings Limited (Nasdaq: BDMD) announced that its management will present at the H.C. Wainwright 28th Annual Global Investment Conference, according to a September 15, 2026 press release. The company focuses on the development and commercialization of minimally invasive treatment solutions.

Why it matters — BDMD watchers would care because the company's management presenting at a major investment conference provides an opportunity for investors to hear directly from leadership.

Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

GlobeNewsWire · 14 Sept 2026positive

Baird Medical highlighted its participation at CIRSE 2026, a leading global interventional radiology congress held in Copenhagen, where it showcased its microwave ablation technology and engaged with the interventional radiology community.

Why it matters — The company's presence and technology showcase at a major international congress reflects its visibility and engagement with the broader interventional radiology field, which is central to its business focus.

Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026

GlobeNewsWire · 3 Sept 2026positive

Baird Medical reported a 25% revenue increase for the six months ended June 30, 2026, driven by significant growth in the United States and other strategic markets. The company also reported positive net income for the period.

Why it matters — BDMD watchers would care because strong revenue growth and positive net income signal improving financial performance, particularly from expansion in the US market.

FAQ

Frequently asked questions about BDMD stock

How does Ticker Nerd's model rank BDMD?

As at 31 Oct 2026, Baird Medical Investment Holdings Ltd. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

What is the BDMD stock forecast for 2030?

No analyst covering Baird Medical Investment Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has BDMD stock performed over the past year?

Baird Medical Investment Holdings Ltd. returned -88.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Baird Medical Investment Holdings Ltd. do?

Baird Medical Investment Holdings Ltd. is a medical technology company focused on the research, development, manufacturing, and sale of microwave ablation devices and related medical products.

What is the latest news on BDMD?

The most recent item we track (GlobeNewsWire, 19 Oct 2026): "Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology". Baird Medical announced regulatory milestones in Vietnam and Egypt for its microwave ablation technology. The company said it continues to advance its global regulatory strategy while supporting U.S. commercial expansion.

Company

About Baird Medical Investment Holdings Ltd.

Baird Medical Investment Holdings Ltd. is a medical technology company focused on the research, development, manufacturing, and sale of microwave ablation devices and related medical products. Its portfolio includes microwave ablation apparatus and needles used in minimally invasive treatment of benign and malignant tumors, such as thyroid nodules, liver cancer, lung cancer, breast lumps, and uterine fibroids. The company also develops devices for soft tissue ablation, serving healthcare providers that perform image-guided and minimally invasive procedures. Baird Medical Investment Holdings Ltd. operates in the medical devices sector, where microwave ablation technology plays a specialized role in interventional oncology and other therapeutic applications. Headquartered in Guangzhou, China, the company is positioned around clinically targeted device innovation and distribution for hospital and physician use.

CEO Ms. Haimei Wu · 146 employees · China · https://bairdmed.com